The infection with human cytomegalovirus (HCMV) is spread worldwide and mostly harmless for immunocompetent individuals. However, it is threatening for individuals whose immune system is still immature (e.g. newborns), immunocompromised (e.g. AIDS or tumour patients) or physiologically or therapeutically immunosuppressed (e.g. pregnancy, patients with organ transplantation). The CMV infection, once acquired, gets persistent as proviral latent infection or as low-level chronic infection. Fighting CMV infection or reactivation has focused on rapid viral diagnosis, antiviral therapy and careful monitoring. However, throughout the whole microbiology, chemotherapy is increasingly restricted by development of resistances. Thus, fighting infectious diseases, the immunologic approach is of increasing relevance. Last year, this journal has launched two special issues on this topic [1, 2] . Concerning research on CMV and other persistent infections, two previous special issues have been continued [3, 4] .
HCMV infection does not provide immunity against reinfection and recurrence. The virus dissemination and transmission is also cell-associated. Leucocyte depletion eliminates CMV infectivity of blood donations. Thus, the development of active or passive immunization against HCMV is difficult and was only partly promising up to date, as far as classical methods were used [5] . Nevertheless, the advent of vaccination against herpes zoster
